Daehwa to patent a direct injectable form of pacliataxel.

Published: 2006-04-24 06:56:00

Updated: 2006-04-24 06:56:00

Daehwa pharmaceutical company announced on April 19 that the company completed a patent registration for a direct injectable form of pacliataxel into the bladder tumor sites, which is the first in such treatment for bladder cancer. So far, the bladder cancer has been treated with a surgical tumor...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK